R. D. Singer, P. J. Scammells / Tetrahedron Letters 42 (2001) 6831–6833
6833
simply adsorbs to the surface of the MnO2 particles
preferentially to CME or thebaine. Regardless of the
interaction between the ionic liquid and MnO2, the
inorganic components of these reactions preferentially
partition into the ionic liquid layer versus the upper
organic layer into which the opiate components prefer-
entially partition. This allows the facile isolation of all
opiates in high yields; hence, the major drawbacks of
previous methods for the MnO2 oxidation of CME to
thebaine have been overcome. Our method requires the
use of less than half the amount of g-MnO2 as reported
elsewhere2b and has proven to be easily reproducible.
The use of sonication has also resulted in decreased
reaction times required for the reaction to go to com-
pletion as compared with unsonicated reactions. Hence,
our method offers significant advantages from an
industrial point of view, especially in the context of
disposal of unreacted MnO2. Depending on the method
used, CME can be converted into thebaine in varying
degrees. It has been reproducibly demonstrated that
using the ionic liquid strictly as an extractant for inor-
ganic impurities and by-products in those reactions in
which CME is converted to thebaine in a covalent,
molecular solvent affords high yields of thebaine. The
actual nature of the interaction between the ionic liquid
and MnO2 is a topic of current investigations. Also
noteworthy is the fact that these reactions represent one
of the first examples of an oxidation reaction conducted
in an ionic liquid.3c,8
Coop, A.; Rice, K. C. Heterocycles 1998, 49, 43; (d) Dung,
J.-S.; Mudryk, B.; Sapino, C.; Sebastian, A. European
Patent Application EP 0 889 045 A1, 1998.
3. (a) Welton, T. Chem. Rev. 1999, 99, 2071; (b) Holbrey, J.
D.; Seddon, K. R. Clean Prod. Process. 1999, 1, 233–236;
(c) Wasserscheid, P.; Keim, W. Angew. Chem., Int. Ed.
2000, 39, 3772–3789.
4. Huddleston, J. G.; Willauer, H. D.; Swatloski, R. P.;
Rogers, R. D. Chem. Commun. 1998, 1765–1766.
5. The moisture stable 1-butyl-3-methylimidazolium was pre-
pared via
a modified version to those preparations
reported in the literature using NaBF4 in acetone; see: (a)
Wilkes, J. S.; Zaworotko, M. J. J. Chem. Soc., Chem.
Commun. 1990, 965; (b) Fuller, J.; Carlin, R. T.; Ostery-
oung, R. A. Electrochem. Soc. 1997, 144, 3881.
6. Scammells, P. J.; Ripper, J. A.; Singer, R. D. Australian
Provisional Patent, PQ9683, 2000.
7. Typical procedure: g-MnO2 Oxidation of CME to the-
baine: CME (0.50 g, 1.6 mmol) was dissolved in 10 mL of
freshly dried and distilled THF followed by addition of
g-MnO2 (0.70 g, 8.0 mmol). The heterogeneous mixture
was then sonicated at ambient temperature for 48 h, under
N2, after which time TLC analysis showed incomplete
reaction. An additional 5 equiv. of g-MnO2 (0.70 g, 8.0
mmol) was then added and the mixture sonicated for a
total of 144 h. 10 mL of 1-butyl-3-methyl-imidazolium
tetrafluoroborate, bmimBF4, were then added to the reac-
tion mixture to extract the MnO2, impurities and
unwanted by-products into a bottom ionic liquid layer.
The reaction mixture was then extracted, first with diethyl-
ether (3×30 mL), and then with ethyl acetate (3×30 mL)
that had formed an upper organic layer above the ionic
liquid layer. The combined organic extracts were then
washed with distilled water to remove residual ionic liquid,
dried with anhydrous MgSO4, filtered, and concentrated in
vacuo to afford 0.5 g of yellow solid. 1H NMR analysis
and comparison to authentic samples then showed >95%
conversion of CME to thebaine with essentially 100%
recovery of opiate from the reaction mixture. Less than 5%
of CME was the only other component present in the
reaction product mixtures determined by 1H NMR. The
yellow color of the products can be attributed to this
unreacted CME. The yellow color of the crude product
could be easily removed via recrystalization from ethanol
with a 93% recovery from crude to give pure thebaine with
a white color.
Acknowledgements
This work was supported by an operating grant from
the Natural Sciences and Engineering Research Council
of Canada and the Centre for Chiral and Molecular
Technologies, Deakin University, Australia. The dona-
tion of codeine methyl ether by Glaxo SmithKline
Australia is greatly appreciated.
References
1. Casy, A. F.; Parfitt, R. T. Opioid Analgesics; Plenum
Press: New York, 1986.
2. (a) Rapoport, H.; Lovell, C. H.; Reist, H. R.; Warren, M.
E. J. Chem. Soc. 1967, 89, 1942; (b) Barber, R. B.;
Rapoport, H. J. Med. Chem. 1975, 18, 1074–1077; (c)
8. Song, C. E.; Roh, E. J. J. Chem. Soc., Chem. Commun.
2000, 837–838.